Head, Market Access Field Team at Amylyx Pharmaceuticals

Cambridge, Massachusetts, United States

Apply Now

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

PharmaceuticalsIndustries

Requirements

Bachelor’s degree required; advanced degree (MBA, MPH, PharmD) preferred
10+ years of experience in Market Access. Must have experience leading a US payer field team at the national level, preferably in launch environments
Proven success in securing access for therapies in rare/orphan diseases is strongly preferred
Ability to inspire trust and drive alignment across cross-functional teams
Deep understanding of U.S. payer landscape, reimbursement pathways (including Medicare, Medicaid, and commercial), and policy environment
Ability to understand and present clinical disease state and product information
Strong analytical and financial acumen

Responsibilities

Serve as a key contributor to launch planning and execution, with a focus on access and reimbursement readiness
Build a high performing, strategic and collaborative account team. Design team structure including roles, target accounts, operating practices and incentives. Recruit, onboard, and develop the team through a successful launch
Lead and enable account teams to establish effective relationships at target public and private payers, PBMs and health system customers
Oversee and participate in customer payer PIE (Pre-approval Information Exchange) and clinical presentations, with the goal of securing favorable formulary access and coverage decisions
Partner with commercial leaders to implement solutions that quickly identify, escalate and resolve patient access issues during launch
Identify coverage and access opportunities and drive cross functional pull through efforts
Represent the market access strategy and payer voice with internal stakeholders as business decisions are made in a fast-paced environment
Foster a culture of trust, integrity and teamwork across all commercial functions. Hold team accountable to do the same

Skills

Market Access

Payer Engagement

Reimbursement

Team Building

Account Management

PBMs

Health Systems

Launch Planning

Pre-approval Information Exchange

Clinical Presentations

Amylyx Pharmaceuticals

Develops treatments for neurodegenerative diseases

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals develops treatments for neurodegenerative diseases, focusing on conditions like Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease (ALZ). Their main product, AMX0035, is currently undergoing clinical trials to assess its effectiveness. The CENTAUR ALS trial showed promising results for ALS patients, using a randomized, double-blind, placebo-controlled design to ensure reliable outcomes. They are also conducting the PEGASUS trial to evaluate AMX0035's safety and effectiveness in Alzheimer's patients. Unlike many competitors, Amylyx emphasizes community engagement and awareness campaigns, such as ALS Awareness Month, to educate the public and foster support for those affected by these diseases. The company's goal is to bring effective therapies to market that improve patient outcomes and enhance the quality of life for individuals suffering from neurodegenerative conditions.

Cambridge, MassachusettsHeadquarters

2013Year Founded

$166.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

51-200Employees

Benefits

Remote Work Options

Risks

Relyvrio's Phase III failure raises concerns about ALS treatment efficacy.

Low stock offering price suggests potential financial instability.

New CCO may disrupt commercialization strategies if not aligned with goals.

Differentiation

Amylyx focuses on neurodegenerative diseases like ALS and Alzheimer's.

AMX0035 is a promising drug for ALS and Alzheimer's treatment.

Amylyx engages in community awareness campaigns for neurodegenerative diseases.

Upsides

Positive Phase II results for AMX0035 in ALS boost its potential.

Partnership with Gubra accelerates drug development for neurodegenerative diseases.

Regulatory support for rare diseases aids Amylyx's Wolfram syndrome efforts.

Land your dream remote job 3x faster with AI

Try Jobo Free